Partial
Mostly Aligned
Patient Risk:
Low
Summary
Most high-level mechanistic, class, and common side-effect claims are generally consistent with the label excerpts provided (e.g., aromatase inhibition; fatigue/dizziness; bone mineral density effects). However, several claims are not fully supported by the supplied label text (e.g., hot flashes and headache specifically; “works by lowering estrogen levels” phrasing; “speed up bone loss” causality; and broad duration/monitoring/treatment suggestions not explicitly stated in the excerpts).
Category Scores
Accurate Statements
Letrozole (Femara) is an oral medicine.
Section 2.1/3 excerpts reference 2.5 mg tablets administered once a day; tablets imply oral administration (2.1, 3).
Letrozole is an aromatase inhibitor.
Section 12.1: “nonsteroidal competitive inhibitor of the aromatase enzyme system.”
Letrozole blocks aromatase.
Section 12.1: “inhibits the conversion of androgens to estrogens” and “inhibitor of the aromatase enzyme system.”
By blocking aromatase, letrozole reduces estrogen production.
Section 12.1: inhibits conversion of androgens to estrogens (indirectly supports reduced estrogen production via mechanism).
Common side effects of aromatase inhibitors like letrozole include fatigue.
Section 5.4 and 6.1: “Fatigue and Dizziness… have been reported.”
Common side effects of aromatase inhibitors like letrozole include joint and muscle pain.
No joint/muscle pain is explicitly listed in the provided excerpts (6.1/5.1/5.4). This item is assessed as unsupported below.
Common side effects of aromatase inhibitors like letrozole can include increased risk of bone thinning (osteoporosis) over time.
Section 5.1: decreases in bone mineral density; includes osteoporosis and bone fractures in trials.
The exact duration of letrozole treatment depends on the treatment plan and whether it is used in the early-stage, metastatic, or extended-adjuvant setting.
Section 2.2 (adjuvant duration unknown; median 5 years; discontinue at relapse) and 2.3 (extended adjuvant; duration unknown; median 60 months; discontinue at tumor relapse) and 2.4 (advanced: continue until tumor progression).
Letrozole is typically taken as a daily oral tablet in breast cancer treatment.
Section 2.1: “one 2.5 mg tablet administered once a day.”
Clinicians may recommend calcium/vitamin D and/or bone-protective therapy when needed for patients taking letrozole.
Section 5.1 supports consideration of monitoring BMD; however, calcium/vitamin D/bone-protective therapy is not explicitly stated in provided excerpts (see unsupported).
Unsupported Statements
Letrozole is used mainly for hormone receptor-positive breast cancer in postmenopausal patients.
Label excerpt supports multiple indicated settings (including hormone receptor positive or unknown locally advanced/metastatic in first-line; and extended adjuvant after tamoxifen). “mainly” and the limitation to “hormone receptor-positive” for all uses is not explicitly supported by the provided indication excerpts.
Letrozole works by lowering estrogen levels in the body.
Label mechanism excerpt describes inhibition of conversion of androgens to estrogens, but the specific phrasing “lowering estrogen levels in the body” is not explicitly stated in the provided excerpts.
Lowering estrogen levels can slow the growth of estrogen-dependent tumors.
The provided label excerpts discuss indications and mechanism, but do not explicitly state tumor growth slowing from estrogen lowering in this wording.
Common side effects of aromatase inhibitors like letrozole include hot flashes.
Hot flashes are not mentioned in the provided adverse reactions/warnings excerpts (5.1/5.4/6).
Common side effects of aromatase inhibitors like letrozole include joint and muscle pain.
Joint and muscle pain are not mentioned in the provided adverse reactions/warnings excerpts.
Common side effects of aromatase inhibitors like letrozole include headache.
Headache is not mentioned in the provided adverse reactions/warnings excerpts.
Because letrozole lowers estrogen, it can speed up bone loss.
While bone mineral density decreases/osteoporosis risk is in the label excerpts, the causal chain “because… lowers estrogen” and “speed up bone loss” is not explicitly stated.
Clinicians often monitor bone density in patients taking letrozole.
Label supports considering monitoring BMD, but does not state “often” as a practice frequency.
Clinicians may recommend calcium/vitamin D and/or bone-protective therapy when needed for patients taking letrozole.
The provided excerpt includes monitoring BMD but does not mention calcium/vitamin D or bone-protective therapy.
Other aromatase inhibitors include anastrozole and exemestane.
The provided label excerpts do not mention other drugs in the class or specific agents.
Other aromatase inhibitors differ in dosing and pharmacology but share the same goal of reducing estrogen.
The goal of “reducing estrogen” is not explicitly stated in the provided excerpts for other aromatase inhibitors; and the label excerpts only define letrozole’s mechanism.
Letrozole is an oral medicine.
If interpreted strictly, the excerpt does not explicitly say “oral medicine,” though tablet administration once daily is consistent. (This item was placed in accurateStatements but could also be treated as partially unsupported; see scoring.)
Contradictions
Important Omissions
Contraindications: pregnancy/FH harm and known hypersensitivity to active substance/excipients.
Importance:
Moderate
Dose administration details: “without regard to meals”; and advanced setting discontinue/continue rule is described, but hepatic impairment dose reduction/every-other-day regimen is not addressed.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Most claims align with label excerpts on mechanism and bone effects; however, several specific side effects are unsupported and some phrasing around estrogen lowering/bone loss is not explicit. No direct contradictions to the provided labeling excerpts were identified.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Mostly Aligned
Primary Issue
Several statements (hot flashes, joint/muscle pain, headache; specific “lower estrogen levels” and “speed up bone loss” phrasing; calcium/vitamin D/bone-protective therapy; monitoring frequency; and class-member examples like anastrozole/exemestane) are not supported by the provided label excerpts.
Suggested Improvement
Restrict safety/side-effect and practice claims to those explicitly present in the excerpts (e.g., bone effects/monitoring BMD consideration; fatigue/dizziness). Use label wording for mechanism (aromatase enzyme inhibition and conversion of androgens to estrogens) and avoid unsupported class-member examples not present in the provided excerpts.